je.st
news
Tag: orphan
Dompe's investigational biotech molecule receives orphan drug...
2015-12-08 10:08:14| Biotech - Topix.net
The Dompe biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency has officially designated recombinant human Nerve Growth Factor - the investigational biotech molecule developed by Dompe based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis. NGF is the first neurotrophic factor to be identified and purified, and represents one of the most interesting topics being studied in medicine today and specifically in ophthalmology.
Tags: drug
receives
biotech
molecule
Top healthcare stock fund focuses on costs, orphan drugs in 2016
2015-11-18 01:43:18| Biotech - Topix.net
Healthcare companies that can either contain costs or develop medications to treat rare diseases, known as orphan drugs, will be the most likely to outperform in the coming year, said John Fraunces, whose Turner Medical Sciences Long/Short fund is among the top performing healthcare funds over the last 5 years. Fraunces, who co-manages the $134 million fund, said he has been increasing his short positions, or bets that shares will decline, on companies that face increased price pressure for high-priced drugs.
PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia
2015-11-03 03:42:29| drugdiscoveryonline Home Page
PixarBio Corporation recently announced that it has filed an application with the US FDA Office of Orphan Products Development, for orphan drug status of our NeuroRelease TN (NR-TN) drug candidate for the treatment of Trigeminal Neuralgia (TN)
Tags: corporation
drug
submission
announces
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now ...
2015-10-10 05:30:50| Biotech - Topix.net
In the world of biopharma, it doesn't take long for a company to copy or mimic a popular, successful drug. In fact, for some less-common diseases, the industry realizes that merely sharing the revenue generated by a small niche may not even be worth the effort, meaning those rare or difficult-to-treat diseases often go completely unaddressed.
Merck KGaA, Darmstadt, Germany, And Pfizer Announce FDA Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma
2015-09-30 08:25:02| drugdiscoveryonline News Articles
Merck KGaA, Darmstadt, Germany, and Pfizer recently announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer
Tags: germany
cell
drug
announce